CN Patent

CN116887822A — 治疗软骨发育不全的方法

Assigned to Quaid Therapeutics Co ltd · Expires 2023-10-13 · 3y expired

What this patent protects

本文提供了通过向患者给予英菲格拉替尼或其药学上可接受的盐来治疗儿科患者的骨骼发育异常例如次软骨发育不全或软骨发育不全的方法。还提供了在治疗儿科患者的骨骼发育异常，例如次软骨发育不全或软骨发育不全中应用的包含单磷酸英菲格拉替尼和药学上可接受的赋形剂的微型片剂。

USPTO Abstract

本文提供了通过向患者给予英菲格拉替尼或其药学上可接受的盐来治疗儿科患者的骨骼发育异常例如次软骨发育不全或软骨发育不全的方法。还提供了在治疗儿科患者的骨骼发育异常，例如次软骨发育不全或软骨发育不全中应用的包含单磷酸英菲格拉替尼和药学上可接受的赋形剂的微型片剂。

Drugs covered by this patent

Patent Metadata

Patent number
CN116887822A
Jurisdiction
CN
Classification
—
Expires
2023-10-13
Drug substance claim
No
Drug product claim
No
Assignee
Quaid Therapeutics Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.